JEFFREY EGERSHENWALDJEFFREY E GERSHENWALD8667GERSHENWALD, JEFFREY EProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Pressler StHouston77030-4008TXAuthorship 1677301Authorship 1683771Authorship 16910817Authorship 1694616Authorship 1703357Authorship 1704689Authorship 1708091Authorship 1709321Authorship 1709844Authorship 1716868Authorship 17196611Authorship 1724205Authorship 1727856Authorship 1732168Authorship 1734053Authorship 1735048Authorship 1742905Authorship 1746236Authorship 1753846Authorship 1755413Authorship 1757166Authorship 1759854Authorship 1762656Authorship 1766018Authorship 1776923Authorship 1778795Authorship 1779016Authorship 17806311Authorship 1788917Authorship 1790313Authorship 17990212Authorship 1799651Authorship 1829014Authorship 1830414Authorship 18494516Authorship 1853783Authorship 1868914Authorship 1882412Authorship 1884609Authorship 1890607Authorship 1890874Authorship 1907525Authorship 19187224Authorship 1929366Authorship 19340913Authorship 1934876Authorship 1942603Authorship 1950317Authorship 195757194041471Gershenwald JE, Bensadoun A, Saluja ABiochimica et biophysica actaMonoclonal antibodies to avian lipoprotein lipase. Purification of the enzyme by immunoaffinity chromatography. Biochim Biophys Acta. 1985 Oct 02; 836(3):286-95.Biochim Biophys Acta1985-10-02T00:00:001985Monoclonal antibodies to avian lipoprotein lipase. Purification of the enzyme by immunoaffinity chromatography.10717634Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A, Kirkwood JM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A, Soong SJ, Thompson JA, Thompson JF, Gershenwald JE, McMasters KMCancerA new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000 Mar 15; 88(6):1484-91.Cancer2000-03-15T00:00:002000A new American Joint Committee on Cancer staging system for cutaneous melanoma.10941558Gershenwald JE, Fischer D, Buzaid ACClinics in plastic surgeryClinical classification and staging. Clin Plast Surg. 2000 Jul; 27(3):361-76, viii.Clin Plast Surg2000-07-01T00:00:002000Clinical classification and staging.11258775Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JEAnnals of surgical oncologySignificance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol. 2001 Mar; 8(2):116-22.Ann Surg Oncol2001-03-01T00:00:002001Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes.11423987Gershenwald JE, Sumner W, Calderone T, Wang Z, Huang S, Bar-Eli MOncogeneDominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene. 2001 Jun 07; 20(26):3363-75.Oncogene2001-06-07T00:00:002001Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo.12124836Sumner WE, Ross MI, Mansfield PF, Lee JE, Prieto VG, Schacherer CW, Gershenwald JECancerImplications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer. 2002 Jul 15; 95(2):354-60.Cancer2002-07-15T00:00:002002Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma.12923915Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JFSeminars in surgical oncologyNew TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003; 21(1):43-52.Semin Surg Oncol2003-01-01T00:00:002003New TNM melanoma staging system: linking biology and natural history to clinical outcomes.15042682Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AYCancerBiochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004 Apr 01; 100(7):1478-83.Cancer2004-04-01T00:00:002004Biochemotherapy in patients with metastatic anorectal mucosal melanoma.15576833Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Hwu P, Ross MIAnnals of surgical oncologyA critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004 Dec; 11(12):1079-84.Ann Surg Oncol2004-12-01T00:00:002004A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma.16568458Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MICancerMetastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006 May 01; 106(9):2012-20.Cancer2006-05-01T00:00:002006Metastatic melanoma to lymph nodes in patients with unknown primary sites.16604476Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Gutman H, Sabel MS, Carlson GW, McMasters KM, Tyler DS, Goydos JS, Eggermont AM, Nieweg OE, Cosimi AB, Riker AI, G Coit DAnnals of surgical oncologyMelanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol. 2006 Jun; 13(6):809-16.Ann Surg Oncol2006-04-12T00:00:002006Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.17000949Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XLArchives of internal medicineEthnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006 Sep 25; 166(17):1907-14.Arch Intern Med2006-09-25T00:00:002006Ethnic differences among patients with cutaneous melanoma.17389530Scolyer RA, Murali R, Gershenwald JE, Cochran AJ, Thompson JFAnnals of oncology : official journal of the European Society for Medical OncologyClinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Ann Oncol. 2007 Apr; 18(4):806-8.Ann Oncol2007-04-01T00:00:002007Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell.18383513Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, Kim K, Webster K, Cella D, Palmer JLCancerProspective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008 May 15; 112(10):2249-57.Cancer2008-05-15T00:00:002008Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire.20126475Rebhun RB, Cheng H, Gershenwald JE, Fan D, Fidler IJ, Langley RRNeoplasia (New York, N.Y.)Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. Neoplasia. 2010 Feb; 12(2):173-82.Neoplasia2010-02-01T00:00:002010Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma.20646783Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem PJournal of the American Academy of DermatologyPathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010 Nov; 63(5):751-61.J Am Acad Dermatol2010-06-19T00:00:002010Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.20975100Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EAClinical cancer research : an official journal of the American Association for Cancer ResearchClinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011 Jan 15; 17(2):229-35.Clin Cancer Res2010-10-25T00:00:002010Clinical correlates of NRAS and BRAF mutations in primary human melanoma.21519009Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC, Morton DL, Sondak VKJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011 Jun 01; 29(16):2199-205.J Clin Oncol2011-04-25T00:00:002011Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database.21858828Ross MI, Gershenwald JEJournal of surgical oncologyEvidence-based treatment of early-stage melanoma. J Surg Oncol. 2011 Sep; 104(4):341-53.J Surg Oncol2011-09-01T00:00:002011Evidence-based treatment of early-stage melanoma.21926416Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, Schacherer CW, Gardner JM, Wang Y, Bishop DT, Barrett JH, GenoMEL Investigators, MacGregor S, Hayward NK, Martin NG, Duffy DL, Q-Mega Investigators, Mann GJ, Cust A, Hopper J, AMFS Investigators, Brown KM, Grimm EA, Xu Y, Han Y, Jing K, McHugh C, Laurie CC, Doheny KF, Pugh EW, Seldin MF, Han J, Wei QHuman molecular geneticsGenome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011 Dec 15; 20(24):5012-23.Hum Mol Genet2011-09-17T00:00:002011Genome-wide association study identifies novel loci predisposing to cutaneous melanoma.22395592Chodkiewicz HM, Cohen PR, Kim KB, Ivan D, Gershenwald JEJournal of drugs in dermatology : JDDA lupus-like reaction to subcutaneous interferon-a at injection sites. J Drugs Dermatol. 2012 Mar; 11(3):393-8.J Drugs Dermatol2012-03-01T00:00:002012A lupus-like reaction to subcutaneous interferon-a at injection sites.23032743Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu PClinical cancer research : an official journal of the American Association for Cancer ResearchSpecific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.Clin Cancer Res2012-10-02T00:00:002012Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.23360207Guan X, Niu J, Liu Z, Wang LE, Amos CI, Lee JE, Gershenwald JE, Grimm EA, Wei QPigment cell & melanoma researchVariants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. Pigment Cell Melanoma Res. 2013 May; 26(3):422-5.Pigment Cell Melanoma Res2013-02-19T00:00:002013Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population.23620404Slingluff CL, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Olson WC, Gaucher A, Chase CM, Grosh WW, Weiss GR, Wagenseller AG, Olszanski AJ, Martin L, Shea SM, Erdag G, Ram P, Gershenwald JE, Weber MJClinical cancer research : an official journal of the American Association for Cancer ResearchClinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res. 2013 Jul 01; 19(13):3611-20.Clin Cancer Res2013-04-25T00:00:002013Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47).24096759Rueth NM, Xing Y, Chiang YJ, Cromwell KD, Ross MI, Lee JE, Gershenwald JE, Royal RE, Cormier JNAnnals of surgeryIs surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014 Jun; 259(6):1215-22.Ann Surg2014-06-01T00:00:002014Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies.24157732Cheng CS, Rai K, Garber M, Hollinger A, Robbins D, Anderson S, Macbeth A, Tzou A, Carneiro MO, Raychowdhury R, Russ C, Hacohen N, Gershenwald JE, Lennon N, Nusbaum C, Chin L, Regev A, Amit INature communicationsSemiconductor-based DNA sequencing of histone modification states. Nat Commun. 2013; 4:2672.Nat Commun2013-01-01T00:00:002013Semiconductor-based DNA sequencing of histone modification states.24259006Curry JL, Davies MA, Calderone TL, Nathanson K, Prieto VG, Gershenwald JEMethods in molecular biology (Clifton, N.J.)Tissue resources for clinical use and marker studies in melanoma. Methods Mol Biol. 2014; 1102:679-95.Methods Mol Biol2014-01-01T00:00:002014Tissue resources for clinical use and marker studies in melanoma.24531700Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC, Morton DL, Atkins MB, Flaherty KT, Sondak VKAnnals of surgical oncologyAge as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.Ann Surg Oncol2014-02-15T00:00:002014Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.Melanoma Medical OncologySurgical OncologyMD AndersonMADELEINEDUVICMADELEINE DUVIC8533DUVIC, MADELEINEProfessor15.10520.00324697761research areas7.135710.0146709198coauthor of456.29452.872160similar to11359selected publicationsJENNIFERWARGOJENNIFER WARGO9904WARGO, JENNIFERAssociate ProfessorMICHAELTETZLAFFMICHAEL TETZLAFF9684TETZLAFF, MICHAELAssociate ProfessorMERRICK IROSSMERRICK I ROSS8502ROSS, MERRICK IProfessorMICHAEL ADAVIESMICHAEL A DAVIES8753DAVIES, MICHAEL AAssociate ProfessorVICTORPRIETOVICTOR PRIETO8828PRIETO, VICTORProfessorJANICE NICOLECORMIERJANICE NICOLE CORMIER8846CORMIER, JANICE NICOLEProfessorAuthorship 2163031Authorship 2169941Authorship 2177951Authorship 2194582Authorship 2195034Authorship 2204972Authorship 2215574Authorship 2216503Authorship 2222832Authorship 2224326Authorship 2224515Authorship 2231954Authorship 2235539Authorship 2241635Authorship 2243074Authorship 2243518Authorship 2245839Authorship 2246063Authorship 2249927Authorship 2250775Authorship 2256154Authorship 2256314Authorship 22568217Authorship 2258108Authorship 2266835Authorship 2269163Authorship 2271174Authorship 2273651Authorship 2278976Authorship 22819711Authorship 2282295Authorship 2291448Authorship 2302716Authorship 23031711Authorship 2303729Authorship 2304916Authorship 2309199Authorship 2320252Authorship 23298413Authorship 2341908Authorship 23549661341237Fong Y, Moldawere LL, He W, Marano M, Keogh CV, Gershenwald J, Lowry SFSurgical oncologyTumour location influences local cytokine production and host metabolism. Surg Oncol. 1992 Feb; 1(1):65-71.Surg Oncol1992-02-01T00:00:001992Tumour location influences local cytokine production and host metabolism.9706139Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M, Lee JJ, Ross MISurgeryImproved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998 Aug; 124(2):203-10.Surgery1998-08-01T00:00:001998Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid.9759577Gershenwald JE, Buzaid AC, Ross MIHematology/oncology clinics of North AmericaClassification and staging of melanoma. Hematol Oncol Clin North Am. 1998 Aug; 12(4):737-65.Hematol Oncol Clin North Am1998-08-01T00:00:001998Classification and staging of melanoma.10761797Gershenwald JE, Mansfield PF, Lee JE, Ross MIAnnals of surgical oncologyRole for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000 Mar; 7(2):160-5.Ann Surg Oncol2000-03-01T00:00:002000Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma.12454112Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KB, Papadopoulos NE, Prieto VG, Ross MIJournal of clinical oncology : official journal of the American Society of Clinical OncologySphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002 Dec 01; 20(23):4555-8.J Clin Oncol2002-12-01T00:00:002002Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma.12744615Bedrosian I, Gershenwald JEThe Surgical clinics of North AmericaSurgical clinical trials in melanoma. Surg Clin North Am. 2003 Apr; 83(2):385-403.Surg Clin North Am2003-04-01T00:00:002003Surgical clinical trials in melanoma.12773013Balch CM, Sober AJ, Soong SJ, Gershenwald JE, AJCC Melanoma Staging CommitteeSeminars in cutaneous medicine and surgeryThe new melanoma staging system. Semin Cutan Med Surg. 2003 Mar; 22(1):42-54.Semin Cutan Med Surg2003-03-01T00:00:002003The new melanoma staging system.12883364McCarty MF, Bielenberg DR, Nilsson MB, Gershenwald JE, Barnhill RL, Ahearne P, Bucana CD, Fidler IJMelanoma researchEpidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. Melanoma Res. 2003 Aug; 13(4):379-87.Melanoma Res2003-08-01T00:00:002003Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis.15070595Pawlik TM, Ross MI, Gershenwald JEAnnals of surgical oncologyLymphatic mapping in the molecular era. Ann Surg Oncol. 2004 Apr; 11(4):362-74.Ann Surg Oncol2004-04-01T00:00:002004Lymphatic mapping in the molecular era.15190500Rousseau DL, Gershenwald JESeminars in oncologyThe new staging system for cutaneous melanoma in the era of lymphatic mapping. Semin Oncol. 2004 Jun; 31(3):415-25.Semin Oncol2004-06-01T00:00:002004The new staging system for cutaneous melanoma in the era of lymphatic mapping.16021533Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JEAnnals of surgical oncologyPredictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005 Aug; 12(8):587-96.Ann Surg Oncol2005-06-16T00:00:002005Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy.16256927Scolyer RA, Thompson JF, McCarthy SW, Gershenwald JE, Ross MI, Cochran AJJournal of the American College of SurgeonsIntraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. J Am Coll Surg. 2005 Nov; 201(5):821-3; author reply 823-4.J Am Coll Surg2005-11-01T00:00:002005Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients.16770531Witte MH, Jones K, Wilting J, Dictor M, Selg M, McHale N, Gershenwald JE, Jackson DGCancer metastasis reviewsStructure function relationships in the lymphatic system and implications for cancer biology. Cancer Metastasis Rev. 2006 Jun; 25(2):159-84.Cancer Metastasis Rev2006-06-01T00:00:002006Structure function relationships in the lymphatic system and implications for cancer biology.16788750Mullen JT, Feng L, Xing Y, Mansfield PF, Gershenwald JE, Lee JE, Ross MI, Cormier JNAnnals of surgical oncologyInvasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006 Jul; 13(7):902-9.Ann Surg Oncol2006-05-22T00:00:002006Invasive squamous cell carcinoma of the skin: defining a high-risk group.16990805Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei QThe Journal of investigative dermatologyGenetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb; 127(2):276-80.J Invest Dermatol2006-09-21T00:00:002006Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma.17063497Gannon CJ, Rousseau DL, Ross MI, Johnson MM, Lee JE, Mansfield PF, Cormier JN, Prieto VG, Gershenwald JECancerAccuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006 Dec 01; 107(11):2647-52.Cancer2006-12-01T00:00:002006Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.17459308Doherty SD, George S, Prieto VG, Gershenwald JE, Duvic MDermatology online journalSegmental neurofibromatosis in association with a large congenital nevus and malignant melanoma. Dermatol Online J. 2006 Dec 10; 12(7):22.Dermatol Online J2006-12-10T00:00:002006Segmental neurofibromatosis in association with a large congenital nevus and malignant melanoma.17557957Cormier JN, Xing Y, Ding M, Cantor SB, Salter KJ, Lee JE, Mansfield PF, Gershenwald JE, Ross MIJournal of clinical oncology : official journal of the American Society of Clinical OncologyCost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007 Jun 10; 25(17):2442-8.J Clin Oncol2007-06-10T00:00:002007Cost effectiveness of adjuvant interferon in node-positive melanoma.17671814Badgwell B, Xing Y, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JNAnnals of surgical oncologyPelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007 Oct; 14(10):2867-75.Ann Surg Oncol2007-08-01T00:00:002007Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.18206850Mittendorf EA, Lim SJ, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JEAmerican journal of surgeryMelanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008 Mar; 195(3):363-8; discussion 368-9.Am J Surg2008-03-01T00:00:002008Melanoma adrenal metastasis: natural history and surgical management.18264782Rebhun RB, Lazar AJ, Fidler IJ, Gershenwald JEClinical & experimental metastasisImpact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Metastasis. 2008; 25(3):191-9.Clin Exp Metastasis2008-02-09T00:00:002008Impact of sentinel lymphadenectomy on survival in a murine model of melanoma.18563783Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei QHuman mutationGenetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008 Dec; 29(12):1443-51.Hum Mutat2008-12-01T00:00:002008Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma.18564433Mortenson MM, Xing Y, Weaver S, Lee JE, Gershenwald JE, Lucci A, Mansfield PF, Ross MI, Cormier JNWorld journal of surgical oncologyFibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol. 2008 Jun 18; 6:63.World J Surg Oncol2008-06-18T00:00:002008Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311).18672361Gershenwald JE, Petrelli NSurgical oncologyFellowship training in surgical oncology--an international affair. Surg Oncol. 2008 Dec; 17(4):277-9.Surg Oncol2008-07-30T00:00:002008Fellowship training in surgical oncology--an international affair.18774657Beadle BM, Guadagnolo BA, Ballo MT, Lee JE, Gershenwald JE, Cormier JN, Mansfield PF, Ross MI, Zagars GKInternational journal of radiation oncology, biology, physicsRadiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1376-82.Int J Radiat Oncol Biol Phys2008-09-05T00:00:002008Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma.18922915Staquicini FI, Tandle A, Libutti SK, Sun J, Zigler M, Bar-Eli M, Aliperti F, P?rez EC, Gershenwald JE, Mariano M, Pasqualini R, Arap W, Lopes JDCancer researchA subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 2008 Oct 15; 68(20):8419-28.Cancer Res2008-10-15T00:00:002008A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans.19309746Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JNCancerLymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009 Jun 01; 115(11):2505-13.Cancer2009-06-01T00:00:002009Lymph node ratio predicts disease-specific survival in melanoma patients.19389531Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, Ross MI, Sondak VK, Thompson JFJournal of the American Academy of DermatologySentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009 May; 60(5):872-5.J Am Acad Dermatol2009-05-01T00:00:002009Sentinel node biopsy and standard of care for melanoma.19430405Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AYMelanoma researchA randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.Melanoma Res2009-02-01T00:00:002009A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.19444817Berman RS, Kurtzman SH, Posner MC, Gershenwald JEJournal of surgical oncologySociety of surgical oncology fellowship training: where we have been, where we are now, and where we are going. J Surg Oncol. 2009 Sep 01; 100(3):179-81.J Surg Oncol2009-09-01T00:00:002009Society of surgical oncology fellowship training: where we have been, where we are now, and where we are going.20336388Chang SB, Askew RL, Xing Y, Weaver S, Gershenwald JE, Lee JE, Royal R, Lucci A, Ross MI, Cormier JNAnnals of surgical oncologyProspective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010 Oct; 17(10):2764-72.Ann Surg Oncol2010-03-25T00:00:002010Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients.21047771Wei X, Prickett TD, Viloria CG, Molinolo A, Lin JC, Cardenas-Navia I, Cruz P, NISC Comparative Sequencing Program, Rosenberg SA, Davies MA, Gershenwald JE, L?pez-Ot?n C, Samuels YMolecular cancer research : MCRMutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res. 2010 Nov; 8(11):1513-25.Mol Cancer Res2010-10-13T00:00:002010Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.21295201Patnana M, Bronstein Y, Szklaruk J, Bedi DG, Hwu WJ, Gershenwald JE, Prieto VG, Ng CSClinical radiologyMultimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol. 2011 Mar; 66(3):224-36.Clin Radiol2011-01-09T00:00:002011Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma.21480241Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, Sleeman JP, Gershenwald JEJournal of surgical oncologyLymphangiogenesis and hemangiogenesis: potential targets for therapy. J Surg Oncol. 2011 May 01; 103(6):489-500.J Surg Oncol2011-05-01T00:00:002011Lymphangiogenesis and hemangiogenesis: potential targets for therapy.21499247Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, NISC Comparative Sequencing Program, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels YNature geneticsExome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011 May; 43(5):442-6.Nat Genet2011-04-15T00:00:002011Exome sequencing identifies GRIN2A as frequently mutated in melanoma.21632855Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LGClinical cancer research : an official journal of the American Association for Cancer ResearchImpact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91.Clin Cancer Res2011-06-01T00:00:002011Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.21914512Askew RL, Swartz RJ, Xing Y, Cantor SB, Ross MI, Gershenwald JE, Palmer JL, Lee JE, Cormier JNValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes ResearchMapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value Health. 2011 Sep-Oct; 14(6):900-6.Value Health2011-06-24T00:00:002011Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights.22453020Boland GM, Gershenwald JECancer journal (Sudbury, Mass.)Sentinel lymph node biopsy in melanoma. Cancer J. 2012 Mar-Apr; 18(2):185-91.Cancer J2012-03-01T00:00:002012Sentinel lymph node biopsy in melanoma.22551296Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FMJournal of translational medicineFuture perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.J Transl Med2012-07-04T00:00:002012Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".24008424Prickett TD, Zerlanko B, Gartner JJ, Parker SCJ, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J, Chen G, Davies MA, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels YThe Journal of investigative dermatologySomatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. J Invest Dermatol. 2014 Feb; 134(2):452-460.J Invest Dermatol2013-09-05T00:00:002013Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin.24521828Iyer JG, Storer BE, Paulson KG, Lemos B, Phillips JL, Bichakjian CK, Zeitouni N, Gershenwald JE, Sondak V, Otley CC, Yu SS, Johnson TM, Liegeois NJ, Byrd D, Sober A, Nghiem PJournal of the American Academy of DermatologyRelationships among primary tumor size, number of?involved nodes, and survival for 8044 cases of?Merkel cell carcinoma. J Am Acad Dermatol. 2014 Apr; 70(4):637-643.J Am Acad Dermatol2014-02-09T00:00:002014Relationships among primary tumor size, number of?involved nodes, and survival for 8044 cases of?Merkel cell carcinoma.Authorship 2358144Authorship 2358421Authorship 2403311Authorship 2403713Authorship 2411062Authorship 2417427Authorship 2418866Authorship 2431555Authorship 2441048Authorship 2448444Authorship 2455393Authorship 2456138Authorship 24634710Authorship 2463835Authorship 2475456Authorship 2480035Authorship 2485585Authorship 2485716Authorship 2487656Authorship 2490119Authorship 2494695Authorship 2495981Authorship 2497762Authorship 2503375Authorship 2504464Authorship 2516468Authorship 2527312Authorship 2531506Authorship 2535471Authorship 2536057Authorship 2546015Authorship 2547111Authorship 2547806Authorship 2548022Authorship 2548487Authorship 2556671Authorship 2566963Authorship 2570612Authorship 2570832Authorship 25743212Authorship 25796332Authorship 25842615Authorship 2587714Authorship 2590377Authorship 2593612Authorship 2601463Authorship 2604186Authorship 2605228Authorship 2616929Authorship 26204661569335He W, Fong Y, Marano MA, Gershenwald JE, Yurt RW, Moldawer LL, Lowry SFThe Journal of infectious diseasesTolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine responses. J Infect Dis. 1992 May; 165(5):859-64.J Infect Dis1992-05-01T00:00:001992Tolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine responses.1695006Gershenwald JE, Fong YM, Fahey TJ, Calvano SE, Chizzonite R, Kilian PL, Lowry SF, Moldawer LLProceedings of the National Academy of Sciences of the United States of AmericaInterleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A. 1990 Jul; 87(13):4966-70.Proc Natl Acad Sci U S A1990-07-01T00:00:001990Interleukin 1 receptor blockade attenuates the host inflammatory response.9626228Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch CM, Ross MIJournal of clinical oncology : official journal of the American Society of Clinical OncologyPatterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60.J Clin Oncol1998-06-01T00:00:001998Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.9632718Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, Bar-Eli MThe Journal of biological chemistryLoss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem. 1998 Jun 26; 273(26):16501-8.J Biol Chem1998-06-26T00:00:001998Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells.9641453Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, Ross MIAnnals of surgical oncologySurgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol. 1998 Jun; 5(4):322-8.Ann Surg Oncol1998-06-01T00:00:001998Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma.10819364Porter GA, Ross MI, Berman RS, Lee JE, Mansfield PF, Gershenwald JEAnnals of surgical oncologySignificance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2000 May; 7(4):256-61.Ann Surg Oncol2000-05-01T00:00:002000Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy.10923009Porter GA, Ross MI, Berman RS, Sumner WE, Lee JE, Mansfield PF, Gershenwald JESurgeryHow many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma? Surgery. 2000 Aug; 128(2):306-11.Surgery2000-08-01T00:00:002000How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma?11314933McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, Noyes RD, Viar V, Cerrito PB, Edwards MJAnnals of surgical oncologySentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001 Apr; 8(3):192-7.Ann Surg Oncol2001-04-01T00:00:002001Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?11713086Esmaeli B, Wang X, Youssef A, Gershenwald JEOphthalmologyPatterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology. 2001 Nov; 108(11):2101-5.Ophthalmology2001-11-01T00:00:002001Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades.11958890Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MIInternational journal of radiation oncology, biology, physicsAdjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2002 Mar 15; 52(4):964-72.Int J Radiat Oncol Biol Phys2002-03-15T00:00:002002Adjuvant irradiation for axillary metastases from malignant melanoma.14712780Kawai Y, Takeda A, Gershenwald JEGan to kagaku ryoho. Cancer & chemotherapy[Effects of vascular endothelial growth factor D on the signaling cascade of sentinel lymphatic endothelial cells from melanoma patients undergoing sentinel lymphadenectomy]. Gan To Kagaku Ryoho. 2003 Dec; 30(13):2141-4.Gan To Kagaku Ryoho2003-12-01T00:00:002003[Effects of vascular endothelial growth factor D on the signaling cascade of sentinel lymphatic endothelial cells from melanoma patients undergoing sentinel lymphadenectomy].15195788Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JFCA: a cancer journal for cliniciansAn evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004 May-Jun; 54(3):131-49; quiz 182-4.CA Cancer J Clin2004-05-01T00:00:002004An evidence-based staging system for cutaneous melanoma.15374553Daley MD, Norman PH, Leak JA, Nguyen DT, Bui TP, Kowalski AM, Srejic U, Popat K, Arens JF, Gershenwald JE, Hunt KK, Kuerer HMJournal of clinical anesthesiaAdverse events associated with the intraoperative injection of isosulfan blue. J Clin Anesth. 2004 Aug; 16(5):332-41.J Clin Anesth2004-08-01T00:00:002004Adverse events associated with the intraoperative injection of isosulfan blue.15780572Pawlik TM, Ross MI, Shaw HM, Thompson JF, Gershenwald JEEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyRe: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. Eur J Surg Oncol. 2005 Apr; 31(3):323-4.Eur J Surg Oncol2005-04-01T00:00:002005Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark.16135473Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XLJournal of clinical oncology : official journal of the American Society of Clinical OncologyPopulation-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005 Sep 01; 23(25):6054-62.J Clin Oncol2005-09-01T00:00:002005Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy.16322269Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli MCancer researchAutomated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 2005 Dec 01; 65(23):11185-92.Cancer Res2005-12-01T00:00:002005Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction.16411225Pawlik TM, Ross MI, Prieto VG, Ballo MT, Johnson MM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JECancerAssessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer. 2006 Feb 15; 106(4):900-6.Cancer2006-02-15T00:00:002006Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma.16618904Leong SP, Accortt NA, Essner R, Ross M, Gershenwald JE, Pockaj B, Hoekstra HJ, Garberoglio C, White RL, Chu D, Biel M, Charney K, Wanebo H, Avisar E, Vetto J, Soong SJ, Sentinel Lymph Node Working GroupArchives of otolaryngology--head & neck surgeryImpact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg. 2006 Apr; 132(4):370-3.Arch Otolaryngol Head Neck Surg2006-04-01T00:00:002006Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients.16621887Li C, Liu Z, Wang LE, Strom SS, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei QCarcinogenesisGenetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006 Sep; 27(9):1894-901.Carcinogenesis2006-04-18T00:00:002006Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma.16782925Aloia TA, Gershenwald JE, Andtbacka RH, Johnson MM, Schacherer CW, Ng CS, Cormier JN, Lee JE, Ross MI, Mansfield PFJournal of clinical oncology : official journal of the American Society of Clinical OncologyUtility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006 Jun 20; 24(18):2858-65.J Clin Oncol2006-06-20T00:00:002006Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma.16984732Rebhun RB, Langley RR, Yokoi K, Fan D, Gershenwald JE, Fidler IJNeoplasia (New York, N.Y.)Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia. 2006 Sep; 8(9):747-57.Neoplasia2006-09-01T00:00:002006Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis.17164380Li C, Hu Z, Liu Z, Wang LE, Strom SS, Gershenwald JE, Lee JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei QCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyPolymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32.Cancer Epidemiol Biomarkers Prev2006-12-01T00:00:002006Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis.17328085Li C, Hu Z, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei QCancerPolymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007 Apr 15; 109(8):1570-8.Cancer2007-04-15T00:00:002007Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study.17389881Gershenwald JE, Ross MINature clinical practice. OncologyIs sentinel-node biopsy superior to nodal observation in melanoma? Nat Clin Pract Oncol. 2007 May; 4(5):278-9.Nat Clin Pract Oncol2007-03-27T00:00:002007Is sentinel-node biopsy superior to nodal observation in melanoma?18049450Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei QThe Journal of investigative dermatologyPolymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol. 2008 Jun; 128(6):1585-8.J Invest Dermatol2007-11-29T00:00:002007Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma.18519701Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff CLCancer researchHuman melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res. 2008 Jun 01; 68(11):4392-7.Cancer Res2008-06-01T00:00:002008Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.18813315Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GBBritish journal of cancerA novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008 Oct 21; 99(8):1265-8.Br J Cancer2008-09-23T00:00:002008A novel AKT3 mutation in melanoma tumours and cell lines.19401063Andtbacka RH, Gershenwald JEJournal of the National Comprehensive Cancer Network : JNCCNRole of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009 Mar; 7(3):308-17.J Natl Compr Canc Netw2009-03-01T00:00:002009Role of sentinel lymph node biopsy in patients with thin melanoma.19967459Scoggins CR, Martin RC, Ross MI, Edwards MJ, Reintgen DS, Urist MM, Gershenwald JE, Sussman JJ, Dirk Noyes R, Goydos JS, Beitsch PD, Ariyan S, Stromberg AJ, Hagendoorn LJ, McMasters KMAnnals of surgical oncologyFactors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010 Mar; 17(3):709-17.Ann Surg Oncol2009-12-05T00:00:002009Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.20187100Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JNCancerConditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010 May 01; 116(9):2234-41.Cancer2010-05-01T00:00:002010Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis.20300965Gershenwald JE, Soong SJ, Balch CM, American Joint Committee on Cancer (AJCC) Melanoma Staging CommitteeAnnals of surgical oncology2010 TNM staging system for cutaneous melanoma...and beyond. Ann Surg Oncol. 2010 Jun; 17(6):1475-7.Ann Surg Oncol2010-06-01T00:00:0020102010 TNM staging system for cutaneous melanoma...and beyond.20369298Bowles TL, Xing Y, Hu CY, Mungovan KS, Askew RL, Chang GJ, Gershenwald JE, Lee JE, Mansfield PF, Ross MI, Cormier JNAnnals of surgical oncologyConditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol. 2010 Aug; 17(8):2015-23.Ann Surg Oncol2010-04-06T00:00:002010Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease.20379784Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P, AJCC Melanoma Task ForceAnnals of surgical oncologyPredicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol. 2010 Aug; 17(8):2006-14.Ann Surg Oncol2010-04-09T00:00:002010Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database.21081714Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JNJournal of the National Cancer InstituteContemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011 Jan 19; 103(2):129-42.J Natl Cancer Inst2010-11-16T00:00:002010Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis.21111955Gershenwald JESurgical oncology clinics of North AmericaPreface. Melanoma. Surg Oncol Clin N Am. 2011 Jan; 20(1):xv-xvi.Surg Oncol Clin N Am2011-01-01T00:00:002011Preface. Melanoma.21111965Davies MA, Gershenwald JESurgical oncology clinics of North AmericaTargeted therapy for melanoma: a primer. Surg Oncol Clin N Am. 2011 Jan; 20(1):165-80.Surg Oncol Clin N Am2011-01-01T00:00:002011Targeted therapy for melanoma: a primer.21542744Gershenwald JE, Ross MIThe New England journal of medicineSentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med. 2011 May 05; 364(18):1738-45.N Engl J Med2011-05-05T00:00:002011Sentinel-lymph-node biopsy for cutaneous melanoma.21858832Balch CM, Gershenwald JE, Soong SJ, Thompson JFJournal of surgical oncologyUpdate on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol. 2011 Sep; 104(4):379-85.J Surg Oncol2011-09-01T00:00:002011Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate.21946352Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels YNature geneticsExon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. Nat Genet. 2011 Sep 25; 43(11):1119-26.Nat Genet2011-09-25T00:00:002011Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.22049339Staquicini FI, Card?-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap WProceedings of the National Academy of Sciences of the United States of AmericaVascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18637-42.Proc Natl Acad Sci U S A2011-11-02T00:00:002011Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients.22198560Liu H, Wei Q, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wang LEMelanoma researchInfluence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res. 2012 Apr; 22(2):169-75.Melanoma Res2012-04-01T00:00:002012Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression.22342785Callender GG, Gershenwald JE, Egger ME, Scoggins CR, Martin RC, Schacherer CW, Edwards MJ, Urist MM, Ross MI, Stromberg AJ, McMasters KMJournal of the American College of SurgeonsA novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg. 2012 Apr; 214(4):608-17; discussion 617-9.J Am Coll Surg2012-02-17T00:00:002012A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model.22817889Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin LCellA landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63.Cell2012-07-20T00:00:002012A landscape of driver mutations in melanoma.22914178Cromwell KD, Ross MI, Xing Y, Gershenwald JE, Royal RE, Lucci A, Lee JE, Cormier JNMelanoma researchVariability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res. 2012 Oct; 22(5):376-85.Melanoma Res2012-10-01T00:00:002012Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.23407396Li C, Yin M, Wang LE, Amos CI, Zhu D, Lee JE, Gershenwald JE, Grimm EA, Wei QThe Journal of investigative dermatologyPolymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol. 2013 Jul; 133(7):1813-21.J Invest Dermatol2013-02-14T00:00:002013Polymorphisms of nucleotide excision repair genes predict melanoma survival.23608449Ross MI, Gershenwald JEClinics in dermatologySentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience. Clin Dermatol. 2013 May-Jun; 31(3):298-310.Clin Dermatol2013-05-01T00:00:002013Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience.23752305Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JNMelanoma researchProspective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res. 2013 Aug; 23(4):290-7.Melanoma Res2013-08-01T00:00:002013Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma.23838920Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VKAnnals of surgical oncologyAge as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.Ann Surg Oncol2013-07-10T00:00:002013Age as a prognostic factor in patients with localized melanoma and regional metastases.23922205Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MACancerClinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer. 2013 Nov 01; 119(21):3821-9.Cancer2013-08-06T00:00:002013Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.24097199Gritz ER, Tripp MK, Peterson SK, Prokhorov AV, Shete SS, Urbauer DL, Fellman BM, Lee JE, Gershenwald JECancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyRandomized controlled trial of a sun protection intervention for children of melanoma survivors. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1813-24.Cancer Epidemiol Biomarkers Prev2013-10-01T00:00:002013Randomized controlled trial of a sun protection intervention for children of melanoma survivors.24369020Chu VH, Tetzlaff MT, Torres-Cabala CA, Prieto VG, Bassett R, Gershenwald JE, McLemore MS, Ivan D, Wang WL, Ross MI, Curry JLBioMed research internationalImpact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. Biomed Res Int. 2013; 2013:898719.Biomed Res Int2013-12-03T00:00:002013Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas.Authorship 2642673Authorship 2654431Authorship 2660513Authorship 2665311Authorship 2666185Authorship 2674846Authorship 2678404Authorship 2678552Authorship 2680442Authorship 2689892Authorship 2694963Authorship 2695604Authorship 2697222Authorship 2699065Authorship 2704232Authorship 2704706Authorship 2706208Authorship 2707021Authorship 27157320Authorship 27221049327744Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli MThe American journal of pathologyExpression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 1997 Oct; 151(4):1105-13.Am J Pathol1997-10-01T00:00:001997Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis.10791854Gershenwald JE, Berman RS, Porter G, Mansfield PF, Lee JE, Ross MIAnnals of surgical oncologyRegional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol. 2000 Apr; 7(3):226-31.Ann Surg Oncol2000-04-01T00:00:002000Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma.14764994Gershenwald JE, Bar-Eli MCancer biology & therapyGene expression profiling of human cutaneous melanoma: are we there yet? Cancer Biol Ther. 2004 Jan; 3(1):121-3.Cancer Biol Ther2004-01-26T00:00:002004Gene expression profiling of human cutaneous melanoma: are we there yet?15389473Goldflam K, Hunt KK, Gershenwald JE, Singletary SE, Mirza N, Kuerer HM, Babiera GV, Ames FC, Ross MI, Feig BW, Sahin AA, Arun B, Meric-Bernstam FCancerContralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 01; 101(9):1977-86.Cancer2004-11-01T00:00:002004Contralateral prophylactic mastectomy. Predictors of significant histologic findings.16034040Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JEJournal of clinical oncology : official journal of the American Society of Clinical OncologyThe risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005 Jul 20; 23(21):4588-90.J Clin Oncol2005-07-20T00:00:002005The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes.16538172Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei QPharmacogenetics and genomicsPolymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006 Apr; 16(4):253-63.Pharmacogenet Genomics2006-04-01T00:00:002006Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma.16794124Pawlik TM, Erasmus JJ, Truong MT, Macapinlac H, Ross MI, Gershenwald JEAJR. American journal of roentgenologyAcne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol. 2006 Jul; 187(1):W117-9.AJR Am J Roentgenol2006-07-01T00:00:002006Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma.16946713Tellez CS, Davis DW, Prieto VG, Gershenwald JE, Johnson MM, McCarty MF, Bar-Eli MThe Journal of investigative dermatologyQuantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol. 2007 Feb; 127(2):387-93.J Invest Dermatol2006-08-31T00:00:002006Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression.17560520Choi EA, Gershenwald JESurgical oncology clinics of North AmericaImaging studies in patients with melanoma. Surg Oncol Clin N Am. 2007 Apr; 16(2):403-30.Surg Oncol Clin N Am2007-04-01T00:00:002007Imaging studies in patients with melanoma.18183598Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei QInternational journal of cancerHaplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84.Int J Cancer2008-05-01T00:00:002008Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study.18228101Ross MI, Gershenwald JEAnnals of surgical oncologyHow should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008 Mar; 15(3):670-3.Ann Surg Oncol2008-01-29T00:00:002008How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?19917835Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VKJournal of clinical oncology : official journal of the American Society of Clinical OncologyFinal version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206.J Clin Oncol2009-11-16T00:00:002009Final version of 2009 AJCC melanoma staging and classification.20655738Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei QEuropean journal of cancer (Oxford, England : 1990)Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15.Eur J Cancer2010-07-23T00:00:002010Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma.21111956Dickson PV, Gershenwald JESurgical oncology clinics of North AmericaStaging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011 Jan; 20(1):1-17.Surg Oncol Clin N Am2011-01-01T00:00:002011Staging and prognosis of cutaneous melanoma.21111959Ross MI, Thompson JF, Gershenwald JESurgical oncology clinics of North AmericaSentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversary. Surg Oncol Clin N Am. 2011 Jan; 20(1):57-78.Surg Oncol Clin N Am2011-01-01T00:00:002011Sentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversary.21480247Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet MJournal of surgical oncologyCutaneous melanoma: a model to study cancer metastasis. J Surg Oncol. 2011 May 01; 103(6):538-49.J Surg Oncol2011-05-01T00:00:002011Cutaneous melanoma: a model to study cancer metastasis.21647761White RL, Ayers GD, Stell VH, Ding S, Gershenwald JE, Salo JC, Pockaj BA, Essner R, Faries M, Charney KJ, Avisar E, Hauschild A, Egberts F, Averbook BJ, Garberoglio CA, Vetto JT, Ross MI, Chu D, Trisal V, Hoekstra H, Whitman E, Wanebo HJ, Debonis D, Vezeridis M, Chevinsky A, Kashani-Sabet M, Shyr Y, Berry L, Zhao Z, Soong SJ, Leong SP, Sentinel Lymph Node Working GroupAnnals of surgical oncologyFactors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011 Dec; 18(13):3593-600.Ann Surg Oncol2011-06-07T00:00:002011Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.22465753Mu H, Calderone TL, Davies MA, Prieto VG, Wang H, Mills GB, Bar-Eli M, Gershenwald JEThe American journal of pathologyLysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol. 2012 May; 180(5):2170-81.Am J Pathol2012-03-30T00:00:002012Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells.22868918Gershenwald JE, Coit DG, Sondak VK, Thompson JFAnnals of surgical oncologyThe challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. Ann Surg Oncol. 2012 Oct; 19(11):3301-3.Ann Surg Oncol2012-10-01T00:00:002012The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas.23901115Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK, NISC Comparative Sequencing Program, Chen G, Elnitski LL, Davies MA, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels YProceedings of the National Academy of Sciences of the United States of AmericaWhole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13481-6.Proc Natl Acad Sci U S A2013-07-30T00:00:002013Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma.Authorship 2727742Authorship 2739142Authorship 2744649Authorship 2746074Authorship 2765193Authorship 2768241Authorship 2771527Authorship 2773318Authorship 27760789481398Talmor M, Hydo L, Gershenwald JG, Barie PSSurgeryBeneficial effects of chest tube drainage of pleural effusion in acute respiratory failure refractory to positive end-expiratory pressure ventilation. Surgery. 1998 Feb; 123(2):137-43.Surgery1998-02-01T00:00:001998Beneficial effects of chest tube drainage of pleural effusion in acute respiratory failure refractory to positive end-expiratory pressure ventilation.10071292Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MIJournal of clinical oncology : official journal of the American Society of Clinical OncologyMulti-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999 Mar; 17(3):976-83.J Clin Oncol1999-03-01T00:00:001999Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.11776489Dessureault S, Soong SJ, Ross MI, Thompson JF, Kirkwood JM, Gershenwald JE, Coit DG, McMasters KM, Balch CM, Reintgen D, American Joint Committee on Cancer (AJCC) Melanoma Staging CommitteeAnnals of surgical oncologyImproved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001 Dec; 8(10):766-70.Ann Surg Oncol2001-12-01T00:00:002001Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy.12095976Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MIAnnals of surgical oncologyPresence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002 Jul; 9(6):587-93.Ann Surg Oncol2002-07-01T00:00:002002Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients.12794025Rousseau DL, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JEAnnals of surgical oncologyRevised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003 Jun; 10(5):569-74.Ann Surg Oncol2003-06-01T00:00:002003Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.15221928McMasters KM, Noyes RD, Reintgen DS, Goydos JS, Beitsch PD, Davidson BS, Sussman JJ, Gershenwald JE, Ross MI, Sunbelt Melanoma TrialJournal of surgical oncologyLessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004 Jul 01; 86(4):212-23.J Surg Oncol2004-07-01T00:00:002004Lessons learned from the Sunbelt Melanoma Trial.16099230Aloia TA, Gershenwald JECurrent problems in surgeryManagement of early-stage cutaneous melanoma. Curr Probl Surg. 2005 Jul; 42(7):460-534.Curr Probl Surg2005-07-01T00:00:002005Management of early-stage cutaneous melanoma.20368546Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VKJournal of clinical oncology : official journal of the American Society of Clinical OncologyMultivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.J Clin Oncol2010-04-05T00:00:002010Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.21451389Moore-Olufemi S, Herzog C, Warneke C, Gershenwald JE, Mansfield P, Ross M, Prieto V, Lally KP, Hayes-Jordan AAnnals of surgeryOutcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg. 2011 Jun; 253(6):1211-5.Ann Surg2011-06-01T00:00:002011Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients.22180178Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MACancerNRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012 Aug 15; 118(16):4014-23.Cancer2011-12-16T00:00:002011NRAS mutation status is an independent prognostic factor in metastatic melanoma.Authorship 2782536Authorship 27837159754762Gershenwald JE, Hunt KK, Kroll SS, Ross MI, Baldwin BJ, Feig BW, Ames FC, Schusterman MA, Singletary SEAnnals of surgical oncologySynchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol. 1998 Sep; 5(6):529-38.Ann Surg Oncol1998-09-01T00:00:001998Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer.Authorship 2872873Authorship 2888922Authorship 2903006Authorship 2906545Authorship 29070617Authorship 29093810Authorship 2916346Authorship 29189810Authorship 2932454Authorship 2950806Authorship 29516716Authorship 29525922Authorship 2960266Authorship 2961497Authorship 3006011Authorship 3010347Authorship 3014632Authorship 3016065Authorship 3033684Authorship 30402714Authorship 304107323714536Sondak VK, Wong SL, Gershenwald JE, Thompson JFAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingEvidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. Am Soc Clin Oncol Educ Book. 2013.Am Soc Clin Oncol Educ Book2013-01-01T00:00:002013Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma.24521113Balch CM, Gershenwald JEThe New England journal of medicineClinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med. 2014 Feb 13; 370(7):663-4.N Engl J Med2014-02-13T00:00:002014Clinical value of the sentinel-node biopsy in primary cutaneous melanoma.24913145Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels YOncotargetA highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget. 2014 May 30; 5(10):2912-7.Oncotarget2014-05-30T00:00:002014A highly recurrent RPS27 5'UTR mutation in melanoma.25113308Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RDPigment cell & melanoma researchBiology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015 Mar; 28(2):135-47.Pigment Cell Melanoma Res2014-09-01T00:00:002014Biology of advanced uveal melanoma and next steps for clinical therapeutics.25148578Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MAThe Journal of investigative dermatologyBeyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.J Invest Dermatol2014-08-22T00:00:002014Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.25165098Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, Lazar AJ, Davies MAClinical cancer research : an official journal of the American Association for Cancer ResearchComplete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.Clin Cancer Res2014-08-27T00:00:002014Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.25196740Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JEInternational journal of cancerThe relationship between blood IL-12p40 level and melanoma progression. Int J Cancer. 2015 Apr 15; 136(8):1874-80.Int J Cancer2014-09-18T00:00:002014The relationship between blood IL-12p40 level and melanoma progression.25348889Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin MJournal of translational medicineFuture perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277.J Transl Med2014-10-28T00:00:002014Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.25515195Gottlieb M, Balk SJ, Geller AC, Gershenwald JEAnnals of surgical oncologyTeens and indoor tanning: time to act on the US Food and Drug Administration's black-box warning. Ann Surg Oncol. 2015 Mar; 22(3):701-3.Ann Surg Oncol2014-12-17T00:00:002014Teens and indoor tanning: time to act on the US Food and Drug Administration's black-box warning.25659743Christianson DR, Dobroff AS, Proneth B, Zurita AJ, Salameh A, Dondossola E, Makino J, Bologa CG, Smith TL, Yao VJ, Calderone TL, O'Connell DJ, Oprea TI, Kataoka K, Cahill DJ, Gershenwald JE, Sidman RL, Arap W, Pasqualini RProceedings of the National Academy of Sciences of the United States of AmericaLigand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proc Natl Acad Sci U S A. 2015 Feb 24; 112(8):2521-6.Proc Natl Acad Sci U S A2015-02-06T00:00:002015Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis.25686251Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli MNature cell biologyReduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol. 2015 Mar; 17(3):311-21.Nat Cell Biol2015-02-16T00:00:002015Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.25779565Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JEJournal of clinical oncology : official journal of the American Society of Clinical OncologyC-reactive protein as a marker of melanoma progression. J Clin Oncol. 2015 Apr 20; 33(12):1389-96.J Clin Oncol2015-03-16T00:00:002015C-reactive protein as a marker of melanoma progression.25809989Cromwell KD, Chiang YJ, Armer J, Heppner PP, Mungovan K, Ross MI, Gershenwald JE, Lee JE, Royal RE, Lucci A, Cormier JNEuropean journal of cancer careIs surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care (Engl). 2015 Sep; 24(5):724-33.Eur J Cancer Care (Engl)2015-03-24T00:00:002015Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema.25848976Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JEThe Journal of investigative dermatologyAssociation of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. J Invest Dermatol. 2015 Sep; 135(9):2266-2272.J Invest Dermatol2015-04-07T00:00:002015Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes.25952338Asare EA, Washington MK, Gress DM, Gershenwald JE, Greene FLCA: a cancer journal for cliniciansImproving the quality of cancer staging. CA Cancer J Clin. 2015 Jul-Aug; 65(4):261-3.CA Cancer J Clin2015-05-07T00:00:002015Improving the quality of cancer staging.26058727Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JLHuman pathologyUtility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.Hum Pathol2015-05-06T00:00:002015Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.26066916Bulger AL, Mayer JE, Gershenwald JE, Guild SR, Gottlieb MA, Geller ACAmerican journal of public healthEnforcement Provisions of Indoor Tanning Bans for Minors: An Analysis of the First 6 US States. Am J Public Health. 2015 Aug; 105(8):e10-2.Am J Public Health2015-06-11T00:00:002015Enforcement Provisions of Indoor Tanning Bans for Minors: An Analysis of the First 6 US States.26477877Voss RK, Cromwell KD, Chiang YJ, Armer JM, Ross MI, Lee JE, Gershenwald JE, Stewart BR, Shaitelman SF, Cormier JNJournal of surgical oncologyThe long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. J Surg Oncol. 2015 Dec; 112(8):834-40.J Surg Oncol2015-10-18T00:00:002015The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients.26563358Gershenwald JE, Guy GPJournal of the National Cancer InstituteStemming the Rising Incidence of Melanoma: Calling Prevention to Action. J Natl Cancer Inst. 2016 Jan; 108(1).J Natl Cancer Inst2015-11-12T00:00:002015Stemming the Rising Incidence of Melanoma: Calling Prevention to Action.26601861Boland GM, Gershenwald JECancer treatment and researchPrinciples of Melanoma Staging. Cancer Treat Res. 2016; 167:131-48.Cancer Treat Res2016-01-01T00:00:002016Principles of Melanoma Staging.26633233Watson M, Thomas CC, Massetti GM, McKenna S, Gershenwald JE, Laird S, Iskander J, Lushniak BMMWR. Morbidity and mortality weekly reportCDC Grand Rounds: Prevention and Control of Skin Cancer. MMWR Morb Mortal Wkly Rep. 2015 Dec 04; 64(47):1312-4.MMWR Morb Mortal Wkly Rep2015-12-04T00:00:002015CDC Grand Rounds: Prevention and Control of Skin Cancer.11766025Esmaeli B, Eicher S, Popp J, Delpassand E, Prieto VG, Gershenwald JEOphthalmic plastic and reconstructive surgerySentinel lymph node biopsy for conjunctival melanoma. Ophthalmic Plast Reconstr Surg. 2001 Nov; 17(6):436-42.Ophthalmic Plast Reconstr Surg2001-11-01T00:00:002001Sentinel lymph node biopsy for conjunctival melanoma.14675203Shen H, Liu Z, Strom SS, Spitz MR, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Ananthaswamy HN, Wei QThe Journal of investigative dermatologyp53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol. 2003 Dec; 121(6):1510-4.J Invest Dermatol2003-12-01T00:00:002003p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma.14716775Bonnen MD, Ballo MT, Myers JN, Garden AS, Diaz EM, Gershenwald JE, Morrison WH, Lee JE, Oswald MJ, Ross MI, Ang KKCancerElective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer. 2004 Jan 15; 100(2):383-9.Cancer2004-01-15T00:00:002004Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck.74Professor14Associate Professor12655537Ballo MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, Schechter NR, Morrison WH, Ross MI, Kian Ang KCancerAdjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003 Apr 01; 97(7):1789-96.Cancer2003-04-01T00:00:002003Adjuvant irradiation for cervical lymph node metastases from melanoma.16540670Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang SCancer researchActivation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006 Mar 15; 66(6):3188-96.Cancer Res2006-03-15T00:00:002006Activation of stat3 in human melanoma promotes brain metastasis.26645196Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Liz?e G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu PCancer discoveryLoss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.Cancer Discov2015-12-08T00:00:002015Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.17121890Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, Lazar AJ, Shen SS, Zhang PS, Reed JA, Gershenwald JE, Raz A, Bar-Eli MClinical cancer research : an official journal of the American Association for Cancer ResearchGalectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res. 2006 Nov 15; 12(22):6709-15.Clin Cancer Res2006-11-15T00:00:002006Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.12591987Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, Spitz MR, Duvic MJournal of the National Cancer InstituteRepair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst. 2003 Feb 19; 95(4):308-15.J Natl Cancer Inst2003-02-19T00:00:002003Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma.12644754Amato M, Esmaeli B, Ahmadi MA, Tehrani MH, Gershenwald J, Ross M, Holds J, Delpassand EOphthalmic plastic and reconstructive surgeryFeasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthalmic Plast Reconstr Surg. 2003 Mar; 19(2):102-6.Ophthalmic Plast Reconstr Surg2003-03-01T00:00:002003Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies.18606982Gershenwald JE, Andtbacka RH, Prieto VG, Johnson MM, Diwan AH, Lee JE, Mansfield PF, Cormier JN, Schacherer CW, Ross MIJournal of clinical oncology : official journal of the American Society of Clinical OncologyMicroscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008 Sep 10; 26(26):4296-303.J Clin Oncol2008-07-07T00:00:002008Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma.16182463Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GKInternational journal of radiation oncology, biology, physicsCombined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):106-13.Int J Radiat Oncol Biol Phys2005-09-22T00:00:002005Combined-modality therapy for patients with regional nodal metastases from melanoma.16368944Wang LE, Xiong P, Strom SS, Goldberg LH, Lee JE, Ross MI, Mansfield PF, Gershenwald JE, Prieto VG, Cormier JN, Duvic M, Clayman GL, Weber RS, Lippman SM, Amos CI, Spitz MR, Wei QJournal of the National Cancer InstituteIn vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31.J Natl Cancer Inst2005-12-21T00:00:002005In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis.18320602Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JNCancerAdjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer. 2008 May 01; 112(9):2030-7.Cancer2008-05-01T00:00:002008Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.18728664Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VGBritish journal of cancerPhase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 02; 99(5):734-40.Br J Cancer2008-08-19T00:00:002008Phase II trial of imatinib mesylate in patients with metastatic melanoma.19222695Petersson F, Diwan AH, Ivan D, Gershenwald JE, Johnson MM, Harrell R, Prieto VGJournal of cutaneous pathologyImmunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol. 2009 Nov; 36(11):1157-63.J Cutan Pathol2009-02-05T00:00:002009Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival.19441164Tellez CS, Shen L, Est?cio MR, Jelinek J, Gershenwald JE, Issa JPMelanoma researchCpG island methylation profiling in human melanoma cell lines. Melanoma Res. 2009 Jun; 19(3):146-55.Melanoma Res2009-06-01T00:00:002009CpG island methylation profiling in human melanoma cell lines.27911979Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MACancerClinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.Cancer2016-12-02T00:00:002016Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.CHARLES MBALCHCHARLES M BALCH12712BALCH, CHARLES MProfessorAuthorship 842265Authorship 842794Authorship 845824Authorship 846595Authorship 847583Authorship 847860Authorship 848491Authorship 848846Authorship 848991Authorship 849737Authorship 849912Authorship 850490Authorship 853463Authorship 854104Authorship 855607Authorship 855863Authorship 857150Authorship 857266Authorship 857340Authorship 857486Authorship 857523Authorship 857977Authorship 858622Authorship 858959Authorship 859098Authorship 859584Authorship 860282Authorship 861886Authorship 862670Authorship 862874Authorship 863102Authorship 863500Authorship 863556Authorship 866592Authorship 867510JAMA - Journal of the American Medical AssociationMelanoma prevention-avoiding indoor tanning and minimizing overexposure to the sun. JAMA - Journal of the American Medical Association. 316:1913-1914.Melanoma prevention-avoiding indoor tanning and minimizing overexposure to the sunAmerican Journal of TransplantationCDC Grand Rounds. American Journal of Transplantation. 16:717-720.CDC Grand RoundsCA Cancer Journal for CliniciansAmerican Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer Journal for Clinicians. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicineAnnals of Surgical OncologyCritical Assessment of Clinical Prognostic Tools in Melanoma. Annals of Surgical Oncology. 1-9.Critical Assessment of Clinical Prognostic Tools in MelanomaJournal of Clinical OncologyReply to J.M. Thomas et al. Journal of Clinical Oncology. 28.Reply to J.M. Thomas et alNew England Journal of MedicineClinical value of the sentinel-node biopsy in primary cutaneous melanoma. New England Journal of Medicine. 370:663-664.Clinical value of the sentinel-node biopsy in primary cutaneous melanomaSurgical ForumInfluence of tumor location on cytokine production and host metabolism. Surgical Forum. 41:450-452.Influence of tumor location on cytokine production and host metabolismCA Cancer Journal for CliniciansState of the science on prevention and screening to reduce melanoma incidence and mortality. CA Cancer Journal for Clinicians. State of the science on prevention and screening to reduce melanoma incidence and mortalityMelanoma. 633-652.MelanomaJournal of Investigative DermatologyMelanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. Journal of Investigative Dermatology. 137:253-257.Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor ThicknessMelanoma Research4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma. Melanoma Research. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanomaCutaneous melanoma. 153-165.Cutaneous melanomaBMC MedicineNovel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine. 14.Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setMedicine (United States)Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanoma. Medicine (United States). 95.Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanomaJournal of the National Cancer InstituteAdjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma. Journal of the National Cancer Institute. 108.Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell CarcinomaSurgical ForumDifferential metabolic response of myocardial versus skeletal muscle during catabolic postburn infection. Surgical Forum. 40:50-52.Differential metabolic response of myocardial versus skeletal muscle during catabolic postburn infectionOncoImmunologyDistinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology. 5.Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaNew England Journal of MedicineThe authors reply. New England Journal of Medicine. 365:571.The authors replyPigment Cell and Melanoma ResearchBiology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell and Melanoma Research. Biology of advanced uveal melanoma and next steps for clinical therapeuticsEuropean Journal of Cancer CareIs surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. European Journal of Cancer Care. 24:724-733.Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedemaClinical Cancer ResearchIntegrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clinical Cancer Research. 15:7538-7546.Integrated molecular and clinical analysis of AKT activation in metastatic melanomaCancer DiscoveryAnalysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockadeClinical Cancer ResearchInflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clinical Cancer Research. 22:3016-3024.Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanomaJournal of Surgical OncologyThe long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. Journal of Surgical Oncology. 112:834-840.The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patientsAmerican Journal of Preventive MedicineCorrelates of Sun Protection and Sunburn in Children of Melanoma Survivors. American Journal of Preventive Medicine. Correlates of Sun Protection and Sunburn in Children of Melanoma SurvivorsMelanoma survivorship management. 219-239.Melanoma survivorship managementCA Cancer Journal for CliniciansThe Eighth Edition AJCC Cancer Staging Manual. CA Cancer Journal for Clinicians. The Eighth Edition AJCC Cancer Staging ManualJournal of Clinical OncologyAssociation of Vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. Journal of Clinical Oncology. 34:1741-1747.Association of Vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive proteinJournal of Translational MedicineFuture perspectives in melanoma research. Journal of Translational Medicine. 12.Future perspectives in melanoma researchJournal of Investigative DermatologyAssociation of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. Journal of Investigative Dermatology. Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and OutcomesCancer DiscoveryCancer Discovery. 6:202-216.Cancer DiscoveryJournal of Investigative DermatologyJournal of Investigative Dermatology. 136:1894-1897.Journal of Investigative DermatologyJournal of Clinical OncologyIn reply. Journal of Clinical Oncology. 26:6012.In replyCancerClinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup> <sup>on-</sup> <sup>V</sup> <sup>600</sup> mutations in cutaneous melanoma patients. Cancer. Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup> <sup>on-</sup> <sup>V</sup> <sup>600</sup> mutations in cutaneous melanoma patientsOperative Techniques in General SurgeryIntroduction. Operative Techniques in General Surgery. 8:65.Introduction12376526Duan Z, Shen H, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Strom SS, Spitz MR, Wei QCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyDNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):1142-3.Cancer Epidemiol Biomarkers Prev2002-10-01T00:00:002002DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma.15952196Ballo MT, Garden AS, Myers JN, Lee JE, Diaz EM, Sturgis EM, Morrison WH, Gershenwald JE, Ross MI, Weber RS, Ang KKHead & neckMelanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005 Aug; 27(8):718-21.Head Neck2005-08-01T00:00:002005Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?22488042Lee I, Fox PS, Ferguson SD, Bassett R, Kong LY, Schacherer CW, Gershenwald JE, Grimm EA, Fuller GN, Heimberger ABOncotargetThe expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44.Oncotarget2012-03-01T00:00:002012The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival.27506587Fang S, Vaysse A, Brossard M, Wang Y, Deng D, Liu Q, Zhang P, Xu K, Li M, Feng R, Liu H, Dang Y, Chen W, Prieto V, Gershenwald JE, Ross MI, Matejka B, Malke J, Haydu LE, Reveille JD, Sui D, Bassett RL, Koshkina N, Avril MF, Lu M, Wei Q, Demenais F, Amos CI, Lee JEThe Journal of investigative dermatologyMelanoma Expression Genes Identified through Genome-Wide Association Study of?Breslow Tumor Thickness. J Invest Dermatol. 2017 01; 137(1):253-257.J Invest Dermatol2016-08-06T00:00:002016Melanoma Expression Genes Identified through Genome-Wide Association Study of?Breslow Tumor Thickness.27001565Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JEJournal of clinical oncology : official journal of the American Society of Clinical OncologyAssociation of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7.J Clin Oncol2016-03-21T00:00:002016Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein.28442307Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JEThe Journal of investigative dermatologyAssociation between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795.J Invest Dermatol2017-04-23T00:00:002017Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes.29097493Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JAScience (New York, N.Y.)Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103.Science2017-11-02T00:00:002017Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Authorship 8875177Authorship 88814516Authorship 88866840Authorship 88934613Authorship 88986655Authorship 8902066D021701Procedures22114080.580974Sentinel Lymph Node BiopsyD008197Procedures36019480.557796Lymph Node Excision29449192McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MAThe Lancet. OncologyAssociation of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.Lancet Oncol2018-02-12T00:00:002018Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.D009367Concepts & IdeasProcedures1303136410.328648Neoplasm StagingAuthorship 90021614D012878Disorders71446250.304279Skin NeoplasmsAuthorship 9035274Authorship 9041496Authorship 9044129Authorship 90463418Authorship 9052714Authorship 90706825Authorship 9076739Authorship 9081252Authorship 9091696Authorship 90927314Authorship 90996119Authorship 9107933Authorship 9111725Authorship 9115064Authorship 9115715Authorship 91277620Authorship 91380836Authorship 9151743Authorship 91591130Authorship 91699611Authorship 9177331Authorship 9177996Authorship 91850335Authorship 9197572Authorship 9208551Authorship 92088815Authorship 9216211Authorship 9217685Authorship 92216723Authorship 92277028Authorship 92506628Authorship 92508035Authorship 9252913Authorship 9268981Authorship 9289952Authorship 92981110Authorship 93005813Authorship 93068227Authorship 93070727Authorship 93169310Authorship 93176127Authorship 9325871Authorship 93309312Authorship 9341026Authorship 9344058Authorship 9345252Authorship 9346484Authorship 9394642Authorship 939777219996208Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JEClinical cancer research : an official journal of the American Association for Cancer ResearchIntegrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res. 2009 Dec 15; 15(24):7538-7546.Clin Cancer Res2009-12-15T00:00:002009Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.24977319Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei QMelanoma research4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. 2016 Apr; 26(2):181-7.Melanoma Res2016-04-01T00:00:0020164-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.26783288Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EAClinical cancer research : an official journal of the American Association for Cancer ResearchInflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24.Clin Cancer Res2016-01-18T00:00:002016Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma.26784705Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, Gimotty PA, Guinney JH, Halabi S, Lazar AJ, Mahar AL, Patel T, Sargent DJ, Weiser MR, Compton C, members of the AJCC Precision Medicine CoreCA: a cancer journal for cliniciansAmerican Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin. 2016 09; 66(5):370-4.CA Cancer J Clin2016-01-19T00:00:002016American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine.26858331McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RC, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Davidson BS, Gershenwald JE, Hagendoorn LJ, Stromberg AJ, Scoggins CRJournal of clinical oncology : official journal of the American Society of Clinical OncologyFinal Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. J Clin Oncol. 2016 Apr 01; 34(10):1079-86.J Clin Oncol2016-02-08T00:00:002016Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.27087480Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZAPigment cell & melanoma researchThe state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 07; 29(4):404-16.Pigment Cell Melanoma Res2016-04-17T00:00:002016The state of melanoma: challenges and opportunities.27232110Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JECA: a cancer journal for cliniciansState of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. 2016 Nov 12; 66(6):460-480.CA Cancer J Clin2016-05-27T00:00:002016State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now.27301722Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JACancer discoveryAnalysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.Cancer Discov2016-06-14T00:00:002016Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.27141370Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JAOncoimmunologyDistinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044.Oncoimmunology2016-02-02T00:00:002016Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.27067306Tripp MK, Peterson SK, Prokhorov AV, Shete SS, Lee JE, Gershenwald JE, Gritz ERAmerican journal of preventive medicineCorrelates of Sun Protection and Sunburn in Children of Melanoma Survivors. Am J Prev Med. 2016 09; 51(3):e77-85.Am J Prev Med2016-04-07T00:00:002016Correlates of Sun Protection and Sunburn in Children of Melanoma Survivors.27188223Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild ANature reviews. Disease primersMelanoma. Nat Rev Dis Primers. 2015 04 23; 1:15003.Nat Rev Dis Primers2015-04-23T00:00:002015Melanoma.26986135Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, Grimm EAMedicineElevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (Baltimore). 2016 Mar; 95(11):e3073.Medicine (Baltimore)2016-03-01T00:00:002016Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma.27052645Mahar AL, Compton C, Halabi S, Hess KR, Gershenwald JE, Scolyer RA, Groome PAAnnals of surgical oncologyCritical Assessment of Clinical Prognostic Tools in Melanoma. Ann Surg Oncol. 2016 09; 23(9):2753-61.Ann Surg Oncol2016-04-06T00:00:002016Critical Assessment of Clinical Prognostic Tools in Melanoma.27245173Bhatia S, Storer BE, Iyer JG, Moshiri A, Parvathaneni U, Byrd D, Sober AJ, Sondak VK, Gershenwald JE, Nghiem PJournal of the National Cancer InstituteAdjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. J Natl Cancer Inst. 2016 09; 108(9).J Natl Cancer Inst2016-05-31T00:00:002016Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base.27251792Najita JS, Swetter SM, Geller AC, Gershenwald JE, Zelen M, Lee SJThe Journal of investigative dermatologySex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (US?Surveillance, Epidemiology, and End Results, 2005-2011). J Invest Dermatol. 2016 09; 136(9):1894-1897.J Invest Dermatol2016-05-29T00:00:002016Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (US?Surveillance, Epidemiology, and End Results, 2005-2011).27824997Gershenwald JE, Halpern AC, Sondak VKJAMAMelanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun. JAMA. 2016 Nov 08; 316(18):1913-1914.JAMA2016-11-08T00:00:002016Melanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun.28081955Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JBSurgeryGeneration of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery. 2017 05; 161(5):1246-1254.Surgery2017-01-09T00:00:002017Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy.27864417Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MTClinical cancer research : an official journal of the American Association for Cancer ResearchTumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104.Clin Cancer Res2016-11-18T00:00:002016Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.27776519Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SEBMC medicineNovel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168.BMC Med2016-10-25T00:00:002016Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.27829081Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SKJAMA dermatologyAssessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. JAMA Dermatol. 2017 Feb 01; 153(2):228-229.JAMA Dermatol2017-02-01T00:00:002017Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors.28094848Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DPCA: a cancer journal for cliniciansThe Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017 Mar; 67(2):93-99.CA Cancer J Clin2017-01-17T00:00:002017The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.28422116Gershenwald JE, Nelson KCNature reviews. Clinical oncologySkin Cancer: Have melanoma and skin cancer finally met their match? Nat Rev Clin Oncol. 2017 05; 14(5):267-268.Nat Rev Clin Oncol2017-04-19T00:00:002017Skin Cancer: Have melanoma and skin cancer finally met their match?28251903Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PAScience translational medicineIntegrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).Sci Transl Med2017-03-01T00:00:002017Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.28591523Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RMThe New England journal of medicineCompletion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 06 08; 376(23):2211-2222.N Engl J Med2017-06-08T00:00:002017Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.28810145Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SECancer cellIntegrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017 08 14; 32(2):204-220.e15.Cancer Cell2017-08-14T00:00:002017Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.28819565Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JANPJ genomic medicineGenomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2.NPJ Genom Med2017-04-07T00:00:002017Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.29028110Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International MeCA: a cancer journal for cliniciansMelanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6):472-492.CA Cancer J Clin2017-10-13T00:00:002017Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.29316429Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SECancer cellIntegrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2018 01 08; 33(1):151.Cancer Cell2018-01-08T00:00:002018Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.29464914Namikawa K, Aung PP, Gershenwald JE, Milton DR, Prieto VGCancer medicineClinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. Cancer Med. 2018 03; 7(3):583-593.Cancer Med2018-02-21T00:00:002018Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center.29470818Zabor EC, Coit D, Gershenwald JE, McMasters KM, Michaelson JS, Stromberg AJ, Panageas KSAnnals of surgical oncologyVariability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. Ann Surg Oncol. 2018 Aug; 25(8):2172-2177.Ann Surg Oncol2018-02-22T00:00:002018Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors.29848573Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez CClinical cancer research : an official journal of the American Association for Cancer ResearchProspective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.Clin Cancer Res2018-05-30T00:00:002018Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.29850954Gershenwald JE, Scolyer RAAnnals of surgical oncologyMelanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol. 2018 Aug; 25(8):2105-2110.Ann Surg Oncol2018-05-30T00:00:002018Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.29361468Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JAThe Lancet. OncologyNeoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.Lancet Oncol2018-01-18T00:00:002018Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.29665799Ascierto PA, Carac? C, Gershenwald JE, Hamid O, Ross M, Sullivan RJ, Puzanov IJournal of translational medicineThe Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. J Transl Med. 2018 04 17; 16(1):101.J Transl Med2018-04-17T00:00:002018The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.29863571Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JEThe American Journal of dermatopathologyCase Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol. 2018 Nov; 40(11):831-835.Am J Dermatopathol2018-11-01T00:00:002018Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall.29923435Keung EZ, Gershenwald JEExpert review of anticancer therapyThe eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018 08; 18(8):775-784.Expert Rev Anticancer Ther2018-08-01T00:00:002018The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care.30281145Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PBCancerChemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44.Cancer2018-10-03T00:00:002018Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials.30259521Bhutiani N, Egger ME, Stromberg AJ, Gershenwald JE, Ross MI, Philips P, Martin RCG, Scoggins CR, McMasters KMJournal of surgical oncologyA model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. J Surg Oncol. 2018 Nov; 118(6):922-927.J Surg Oncol2018-09-27T00:00:002018A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node.30392755Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina TJournal of the American Academy of DermatologyGuidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019 01; 80(1):208-250.J Am Acad Dermatol2018-11-01T00:00:002018Guidelines of care for the management of primary cutaneous melanoma.30105437Gershenwald JE, Scolyer RAAnnals of surgical oncologyCorrection to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol. 2018 12; 25(Suppl 3):993-994.Ann Surg Oncol2018-12-01T00:00:002018Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.30115691Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AECancer researchErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res. 2018 10 01; 78(19):5680-5693.Cancer Res2018-08-16T00:00:002018ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.29776954Bezrookove V, Nosrati M, Miller JR, De Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, Davies MA, Schadendorf D, Kashani-Sabet MClinical cancer research : an official journal of the American Association for Cancer ResearchRole of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clin Cancer Res. 2018 09 01; 24(17):4119-4125.Clin Cancer Res2018-05-18T00:00:002018Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.29945191Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RAAnnals of oncology : official journal of the European Society for Medical OncologyPathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 08 01; 29(8):1861-1868.Ann Oncol2018-08-01T00:00:002018Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.30231343LoConte NK, Gershenwald JE, Thomson CA, Crane TE, Harmon GE, Rechis RAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingLifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:88-100.Am Soc Clin Oncol Educ Book2018-05-23T00:00:002018Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction.30646045Ferguson PM, Gershenwald JE, Scolyer RAJAMA network openStaging of Cutaneous Melanoma: Is There Room for Further Improvement? JAMA Netw Open. 2018 05 18; 1(1):e180086.JAMA Netw Open2018-05-18T00:00:002018Staging of Cutaneous Melanoma: Is There Room for Further Improvement?30703459Nelson KC, Gershenwald JE, Savory SA, Wilson JM, Simon JM, Burton EM, Haydu LEJournal of the American Academy of DermatologyTelementoring and smartphone-based answering systems to optimize dermatology resident dermoscopy education. J Am Acad Dermatol. 2019 Aug; 81(2):e27-e28.J Am Acad Dermatol2019-01-29T00:00:002019Telementoring and smartphone-based answering systems to optimize dermatology resident dermoscopy education.30297909Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JANature medicineNeoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.Nat Med2018-10-08T00:00:002018Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.30361510Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JANature medicineAuthor Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.Nat Med2018-12-01T00:00:002018Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.30361511Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JANature medicinePublisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.Nat Med2018-12-01T00:00:002018Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.D008545Disorders68053010.290119MelanomaDermatologyPathologyAuthorship 9410767Authorship 9416012Authorship 9425512030863861Dessinioti C, Dimou N, Geller AC, Stergiopoulou A, Lo S, Keim U, Gershenwald JE, Haydu LE, Ribero S, Quaglino P, Puig S, Malvehy J, Kandolf-Sekulovic L, Radevic T, Kaufmann R, Meister L, Nagore E, Traves V, Champsas GG, Plaka M, Dreno B, Varey E, Ramirez DM, Dummer R, Mangana J, Hauschild A, Egberts F, Peris K, Del Regno L, Forsea AM, Zurac SA, Vieira R, Brinca A, Zalaudek I, Deinlein T, Linos E, Evangelou E, Thompson JF, Scolyer RA, Garbe C, Stratigos AJJournal of the National Cancer InstituteDistinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. J Natl Cancer Inst. 2019 12 01; 111(12):1314-1322.J Natl Cancer Inst2019-12-01T00:00:002019Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers.30737667Berman RS, Gershenwald JEAnnals of surgical oncologyCompletion Node Dissection for Sentinel Node-Positive Melanoma: Can a Systematic Review Bring One Discussion to a Close While Leaving the Broader Conversation Still Open? Ann Surg Oncol. 2019 Apr; 26(4):921-923.Ann Surg Oncol2019-02-08T00:00:002019Completion Node Dissection for Sentinel Node-Positive Melanoma: Can a Systematic Review Bring One Discussion to a Close While Leaving the Broader Conversation Still Open?30787016Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MACancer discoveryMolecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.Cancer Discov2019-02-20T00:00:002019Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.Authorship 942818430884440Haydu LE, Thompson JF, Scolyer RA, Gershenwald JEEuropean journal of cancer (Oxford, England : 1990)Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. Eur J Cancer. 2019 05; 112:9-11.Eur J Cancer2019-03-15T00:00:002019Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system.Authorship 944250330729519Asare EA, Grubbs EG, Gershenwald JE, Greene FL, Aloia TAJournal of surgical oncologySetting the "stage" for Surgical Oncology fellows: Pierre Denoix and TNM staging. J Surg Oncol. 2019 Jun; 119(7):823.J Surg Oncol2019-02-06T00:00:002019Setting the "stage" for Surgical Oncology fellows: Pierre Denoix and TNM staging.Authorship 9467811331058252Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JEJCO precision oncologyBiological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol. 2018; 2018.JCO Precis Oncol2018-06-14T00:00:002018Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.Authorship 948253731168736Lillemoe HA, Scally CP, Adams CL, Bednarski BK, Balch CM, Aloia TA, Gershenwald JE, Lee JE, Grubbs EGAnnals of surgical oncologyComplex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility. Ann Surg Oncol. 2019 Sep; 26(9):2667-2674.Ann Surg Oncol2019-06-05T00:00:002019Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility.Authorship 948830831176707Fang S, Xu T, Xiong M, Zhou X, Wang Y, Haydu LE, Ross MI, Gershenwald JE, Prieto VG, Cormier JN, Wargo J, Sui D, Wei Q, Amos CI, Lee JEThe Journal of investigative dermatologyRole of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. J Invest Dermatol. 2019 11; 139(11):2352-2358.e3.J Invest Dermatol2019-06-07T00:00:002019Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression.Authorship 9510621431267972Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GVThe Lancet. OncologyNeoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.Lancet Oncol2019-07-01T00:00:002019Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.Authorship 952008231306154Scolyer RA, Gershenwald JE, Thompson JFThe American journal of surgical pathologyIsolated Imunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. Am J Surg Pathol. 2019 10; 43(10):1442-1444.Am J Surg Pathol2019-10-01T00:00:002019Isolated Imunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System.Authorship 9533181931383963Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MTModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncPrognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.Mod Pathol2019-08-05T00:00:002019Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.Authorship 954334831442076Malke JC, Jin S, Camp SP, Lari B, Kell T, Simon JM, Prieto VG, Gershenwald JE, Haydu LEJCO clinical cancer informaticsEnhancing Case Capture, Quality, and Completeness of Primary Melanoma Pathology Records via Natural Language Processing. JCO Clin Cancer Inform. 2019 08; 3:1-11.JCO Clin Cancer Inform2019-08-01T00:00:002019Enhancing Case Capture, Quality, and Completeness of Primary Melanoma Pathology Records via Natural Language Processing.Authorship 956235931570567Namikawa K, Aung PP, Milton DR, Tetzlaff MT, Torres-Cabala CA, Curry JL, Nagarajan P, Ivan D, Ross M, Gershenwald JE, Prieto VGClinical cancer research : an official journal of the American Association for Cancer ResearchCorrelation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clin Cancer Res. 2019 12 15; 25(24):7585-7593.Clin Cancer Res2019-09-30T00:00:002019Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma.Authorship 957533631630191Fang S, Lu J, Zhou X, Wang Y, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Sui D, Amos CI, Lee JECarcinogenesisFunctional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis. 2020 06 17; 41(4):452-457.Carcinogenesis2020-06-17T00:00:002020Functional annotation of melanoma risk loci identifies novel susceptibility genes.Authorship 960893331714593Abudu B, Cook KA, Gershenwald JE, Cohen PR, Geller ACCancerQuantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. Cancer. 2020 02 15; 126(4):775-781.Cancer2019-11-12T00:00:002019Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States.Authorship 961473331758078Scolyer RA, Rawson RV, Gershenwald JE, Ferguson PM, Prieto VGModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMelanoma pathology reporting and staging. Mod Pathol. 2020 01; 33(Suppl 1):15-24.Mod Pathol2019-11-22T00:00:002019Melanoma pathology reporting and staging.Authorship 9746061231870188Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AMFuture oncology (London, England)KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.Future Oncol2019-12-24T00:00:002019KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.Authorship 97579911Authorship 9758602431940493Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AECell reportsFOXD3 Regulates VISTA Expression in Melanoma. Cell Rep. 2020 01 14; 30(2):510-524.e6.Cell Rep2020-01-14T00:00:002020FOXD3 Regulates VISTA Expression in Melanoma.31942075Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Saut?s-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JANatureB cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.Nature2020-01-15T00:00:002020B cells and tertiary lymphoid structures promote immunotherapy response.Authorship 9766072731990608Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MAJournal of clinical oncology : official journal of the American Society of Clinical OncologyCumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.J Clin Oncol2020-01-28T00:00:002020Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.Authorship 9773501632015020Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MIClinical cancer research : an official journal of the American Association for Cancer ResearchCirculating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895.Clin Cancer Res2020-02-03T00:00:002020Circulating Tumor Cells and Early Relapse in Node-positive Melanoma.Authorship 977967232061122Keung EZ, Gershenwald JEJournal of the National Cancer InstituteClinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. J Natl Cancer Inst. 2020 09 01; 112(9):875-885.J Natl Cancer Inst2020-09-01T00:00:002020Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.Authorship 987503332299446Ascierto PA, Agarwala SS, Eggermont A, Gershenwald JE, Grob JJ, Hamid O, Michielin O, Postow M, Puzanov I, Zarour HM, Carac? C, Testori AJournal of translational medicineThe Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. J Transl Med. 2020 04 16; 18(1):171.J Transl Med2020-04-16T00:00:002020The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.Authorship 988798832374709Alberg AJ, LoConte NK, Foxhall L, Weinstock MA, Gomez SL, Francisco M, Moushey EA, Gershenwald JEJCO oncology practiceAmerican Society of Clinical Oncology Policy Statement on Skin Cancer Prevention. JCO Oncol Pract. 2020 08; 16(8):490-499.JCO Oncol Pract2020-05-06T00:00:002020American Society of Clinical Oncology Policy Statement on Skin Cancer Prevention.Authorship 9916251232530761Lo SN, Ma J, Scolyer RA, Haydu LE, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Ch'ng S, Mann GJ, Gershenwald JE, Thompson JF, Varey AHRJournal of clinical oncology : official journal of the American Society of Clinical OncologyImproved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol. 2020 08 20; 38(24):2719-2727.J Clin Oncol2020-06-12T00:00:002020Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram.Authorship 994556532675519Day RW, Taylor BM, Bednarski BK, Tzeng CD, Gershenwald JE, Lee JE, Grubbs EGAnnals of surgeryVirtual Interviews for Surgical Training Program Applicants During COVID-19: Lessons Learned and Recommendations. Ann Surg. 2020 08; 272(2):e144-e147.Ann Surg2020-08-01T00:00:002020Virtual Interviews for Surgical Training Program Applicants During COVID-19: Lessons Learned and Recommendations.Authorship 9956062332725204Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SMJAMA dermatologyPrognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011.JAMA Dermatol2020-09-01T00:00:002020Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.Authorship 9963401832739408Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RAAnnals of oncology : official journal of the European Society for Medical OncologyHistopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020 11; 31(11):1569-1579.Ann Oncol2020-07-31T00:00:002020Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.Authorship 9990511132891326Tzeng CD, Tran Cao HS, Roland CL, Teshome M, Bednarski BK, Ikoma N, Graham PH, Keung EZ, Scally CP, Katz MHG, Gershenwald JE, Lee JE, Vauthey JNSurgical oncologySurgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach. Surg Oncol. 2020 Sep; 34:182-185.Surg Oncol2020-04-28T00:00:002020Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach.Authorship 10021081533016647Fischer GM, Carapeto FCL, Joon AY, Haydu LE, Chen H, Wang F, Van Arnam JS, McQuade JL, Wani K, Kirkwood JM, Thompson JF, Tetzlaff MT, Lazar AJ, Tawbi HA, Gershenwald JE, Scolyer RA, Long GV, Davies MACancer medicineMolecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.Cancer Med2020-10-05T00:00:002020Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker.33414132Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G, Melanoma Research FoundationClinical cancer research : an official journal of the American Association for Cancer ResearchThe State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697.Clin Cancer Res2021-01-07T00:00:002021The State of Melanoma: Emergent Challenges and Opportunities.Authorship 10094076Authorship 1009499333454993Dessinioti C, Geller AC, Stergiopoulou A, Dimou N, Lo S, Keim U, Gershenwald JE, Haydu LE, Dummer R, Mangana J, Hauschild A, Egberts F, Vieira R, Brinca A, Zalaudek I, Deinlein T, Evangelou E, Thompson JF, Scolyer RA, Peris K, Garbe C, Stratigos AJThe British journal of dermatologyA multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences. Br J Dermatol. 2021 07; 185(1):101-109.Br J Dermatol2021-04-01T00:00:002021A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences.33463835Goepfert RP, Myers JN, Gershenwald JEHead & neckUpdates in the evidence-based management of cutaneous melanoma. Head Neck. 2020 11; 42(11):3396-3404.Head Neck2020-08-16T00:00:002020Updates in the evidence-based management of cutaneous melanoma.Authorship 1009795333484834Faries MB, Testori AAE, Gershenwald JEAnnals of oncology : official journal of the European Society for Medical OncologySentinel node biopsy for primary cutaneous melanoma. Ann Oncol. 2021 03; 32(3):290-292.Ann Oncol2021-01-20T00:00:002021Sentinel node biopsy for primary cutaneous melanoma.Authorship 10112601133577643Ronen S, Al-Rohil RN, Keiser E, Jour G, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Middleton LP, Torres-Cabala CA, Gershenwald JE, Aung PP, Prieto VGArchives of pathology & laboratory medicineDiscordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management. Arch Pathol Lab Med. 2021 12 01; 145(12):1505-1515.Arch Pathol Lab Med2021-12-01T00:00:002021Discordance in Diagnosis of Melanocytic Lesions and Its Impact on Clinical Management.Authorship 10151691Authorship 1015174433826746Gershenwald JECancerActive surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned ? and still learning. Cancer. 2021 07 01; 127(13):2177-2180.Cancer2021-04-07T00:00:002021Active surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned ? and still learning.33827575Ascierto PA, Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Carac? C, Osman I, Puzanov IJournal of translational medicineThe "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med. 2021 04 07; 19(1):142.J Transl Med2021-04-07T00:00:002021The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020.Authorship 1016372733856603Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BAAnnals of surgical oncologyNodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul; 28(7):3480-3489.Ann Surg Oncol2021-04-15T00:00:002021Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era.Authorship 101695521Authorship 1017157733907234Cheng LY, Haydu LE, Song P, Nie J, Tetzlaff MT, Kwong LN, Gershenwald JE, Davies MA, Zhang DYScientific reportsHigh sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci Rep. 2021 04 27; 11(1):9043.Sci Rep2021-04-27T00:00:002021High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.Authorship 1019398734037915Rechis R, Oestman KB, Caballero E, Brewster A, Walsh MT, Basen-Engquist K, Gershenwald JE, Tektiridis JH, Moreno M, Williams PA, Treiman K, Garza PD, Hawk ECancer causes & control : CCCBe Well Communities?: mobilizing communities to promote wellness and stop cancer before it starts. Cancer Causes Control. 2021 Aug; 32(8):859-870.Cancer Causes Control2021-05-26T00:00:002021Be Well Communities?: mobilizing communities to promote wellness and stop cancer before it starts.Authorship 10235216334239137Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JANature medicineGut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.Nat Med2021-07-08T00:00:002021Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.Authorship 103403513Authorship 10341252334771465Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JACancersIdentification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel). 2021 Oct 22; 13(21).Cancers (Basel)2021-10-22T00:00:002021Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes.34777916White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JAOncoimmunologyShort-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.Oncoimmunology2021-11-06T00:00:002021Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma.Authorship 103550213Authorship 103590265Authorship 10359931234904258Witt RG, Cope B, Chiang YJ, Newhook T, Lillemoe H, Tzeng CD, Chen IB, Fisher SB, Lucci A, Wargo JA, Lee JE, Ross MI, Gershenwald JE, Robinson J, Keung EZJournal of surgical oncologyUtilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol. 2022 Mar; 125(4):719-729.J Surg Oncol2021-12-14T00:00:002021Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy.34952092Wang Y, Ramachandran V, Sui D, Xu K, Haydu LE, Fang S, McQuade JL, Fisher SB, Lucci A, Keung EZ, Wargo J, Gershenwald JE, Ross MI, Lee JEThe Journal of investigative dermatologyEvaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol. 2022 07; 142(7):2046-2049.e3.J Invest Dermatol2021-12-21T00:00:002021Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker.34941392Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JAScience (New York, N.Y.)Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.Science2021-12-23T00:00:002021Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.Authorship 10382236Authorship 10390741435089452van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI, International Neoadjuvant Melanoma Consortium (INMC)Annals of surgical oncologyNeoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Jun; 29(6):3694-3708.Ann Surg Oncol2022-01-28T00:00:002022Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).35278716Mitra D, Rao PK, Nagarajan P, Bishop AJ, Farooqi AS, Gershenwald JE, Wargo J, Keung EZ, Fisher SB, Amaria RN, Davies MA, Ross MI, Guadagnolo BAPractical radiation oncologyOutcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):437-445.Pract Radiat Oncol2022-03-09T00:00:002022Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020.Authorship 104362121Authorship 10439641435426590van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI, International Neoadjuvant Melanoma Consortium (INMC)Annals of surgical oncologyCorrection to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Aug; 29(8):5241-5242.Ann Surg Oncol2022-08-01T00:00:002022Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC).35397739Cui C, Lian B, Zhang X, Wu D, Li K, Si L, Yang Y, Tian H, Zhou L, Chi Z, Sheng X, Kong Y, Mao L, Wang X, Bai X, Yan X, Li S, Dai J, Tang B, Wei X, Gershenwald JE, Balch CM, Guo JAnnals of surgical oncologyAn Evidence-Based Staging System for Mucosal Melanoma: A Proposal. Ann Surg Oncol. 2022 Aug; 29(8):5221-5234.Ann Surg Oncol2022-04-09T00:00:002022An Evidence-Based Staging System for Mucosal Melanoma: A Proposal.12734081Scaife CL, Curley SA, Izzo F, Marra P, Delrio P, Daniele B, Cremona F, Gershenwald JE, Chase JL, Lozano RD, Patt YZ, Fornage BD, Vauthey JN, Woodall ML, Gonzalez KB, Ellis LMAnnals of surgical oncologyFeasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol. 2003 May; 10(4):348-54.Ann Surg Oncol2003-05-01T00:00:002003Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer.16538410Pawlik TM, Zorzi D, Abdalla EK, Clary BM, Gershenwald JE, Ross MI, Aloia TA, Curley SA, Camacho LH, Capussotti L, Elias D, Vauthey JNAnnals of surgical oncologyHepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006 May; 13(5):712-20.Ann Surg Oncol2006-03-14T00:00:002006Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease.Authorship 10457725Authorship 1046164735538491Ascierto PA, Warner AB, Blank C, Carac? C, Demaria S, Gershenwald JE, Khushalani NI, Long GV, Luke JJ, Mehnert JM, Robert C, Rutkowski P, Tawbi HA, Osman I, Puzanov IJournal of translational medicineThe "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. J Transl Med. 2022 05 10; 20(1):200.J Transl Med2022-05-10T00:00:002022The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.35583689Bartlett EK, Grossman D, Swetter SM, Leachman SA, Curiel-Lewandrowski C, Dusza SW, Gershenwald JE, Kirkwood JM, Tin AL, Vickers AJ, Marchetti MAAnnals of surgical oncologyClinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. Ann Surg Oncol. 2022 Sep; 29(9):5948-5956.Ann Surg Oncol2022-05-18T00:00:002022Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts.Authorship 10480623335705814Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JANatureAndrogen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.Nature2022-06-15T00:00:002022Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.Authorship 10503543135810190Andrews MC, Oba J, Wu CJ, Zhu H, Karpinets T, Creasy CA, Forget MA, Yu X, Song X, Mao X, Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ, Haydu LE, Bustos MA, Shen J, Chen Y, Morgan MB, Wargo JA, Kwong LN, Haymaker CL, Grimm EA, Hwu P, Hoon DSB, Zhang J, Gershenwald JE, Davies MA, Futreal PA, Bernatchez C, Woodman SENature communicationsMulti-modal molecular programs regulate melanoma cell state. Nat Commun. 2022 07 09; 13(1):4000.Nat Commun2022-07-09T00:00:002022Multi-modal molecular programs regulate melanoma cell state.Authorship 10543578Authorship 105787734Authorship 105937135Authorship 105558713Authorship 106069822Authorship 105804237Authorship 10583381836265502Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA, KEYNOTE-716 InvestigatorsThe Lancet. OncologyPembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022 11; 23(11):1378-1388.Lancet Oncol2022-10-18T00:00:002022Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.36289334Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HANatureNeoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.Nature2022-10-26T00:00:002022Neoadjuvant relatlimab and nivolumab in resectable melanoma.36166093Hahn AW, Menk AV, Rivadeneira DB, Augustin RC, Xu M, Li J, Wu X, Mishra AK, Gide TN, Quek C, Zang Y, Spencer CN, Menzies AM, Daniel CR, Hudgens CW, Nowicki T, Haydu LE, Khan MAW, Gopalakrishnan V, Burton EM, Malke J, Simon JM, Bernatchez C, Putluri N, Woodman SE, Vashisht Gopal YN, Guerrieri R, Fischer GM, Wang J, Wani KM, Thompson JF, Lee JE, Hwu P, Ajami N, Gershenwald JE, Long GV, Scolyer RA, Tetzlaff MT, Lazar AJ, Schadendorf D, Wargo JA, Kirkwood JM, DeBerardinis RJ, Liang H, Futreal A, Zhang J, Wilmott JS, Peng W, Davies MA, Delgoffe GM, Najjar YG, McQuade JLClinical cancer research : an official journal of the American Association for Cancer ResearchObesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.Clin Cancer Res2023-01-04T00:00:002023Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.36075285Wei X, Chen Y, Yao H, Wu D, Li H, Zhang R, Chi Z, Cui C, Bai X, Mao L, Qi Z, Li K, Lan S, Chen L, Guo R, Yao X, Lian B, Kong Y, Dai J, Tang B, Wang X, Gershenwald JE, Balch CM, Guo J, Si LJournal of the American Academy of DermatologyPrognostic impact of Breslow thickness in acral melanoma: A retrospective analysis. J Am Acad Dermatol. 2022 12; 87(6):1287-1294.J Am Acad Dermatol2022-09-06T00:00:002022Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis.35921122Multicenter Selective Lymphadenectomy Trials Study Group, Crystal JS, Thompson JF, Hyngstrom J, Carac? C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Neves RI, Rossi CR, Kane JM, Trocha S, Wright F, Byrd DR, Matter M, Hsueh EC, MacKenzie-Ross A, Kelley M, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Ariyan CE, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, McMasters KM, O'Donoghue C, van der Westhuizen A, Sardi A, Barth R, Barone R, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Molina M, Testori AAE, Foshag LJ, Van Kreuningen L, Wang HJ, Sim MS, Scolyer RA, Elashoff DE, Cochran AJ, Faries MBJAMA surgeryTherapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA Surg. 2022 09 01; 157(9):835-842.JAMA Surg2022-09-01T00:00:002022Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.36627494Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JANatureAuthor Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3.Nature2023-01-01T00:00:002023Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.36510640Hasanov M, Milton DR, Davies AB, Sirmans E, Saberian C, Posada EL, Opusunju S, Gershenwald JE, Torres-Cabala CA, Burton EM, Colen RR, Huse JT, Glitza Oliva IC, Chung C, McAleer MF, McGovern SL, Yeboa DN, Kim BYS, Prabhu SS, McCutcheon IE, Weinberg JS, Lang FF, Tawbi HA, Li J, Haydu LE, Davies MA, Ferguson SDNeuro-oncologyChanges in outcomes and factors associated with survival in melanoma patients with brain metastases. Neuro Oncol. 2023 Jul 06; 25(7):1310-1320.Neuro Oncol2023-07-06T00:00:002023Changes in outcomes and factors associated with survival in melanoma patients with brain metastases.Authorship 10652911436894629Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HANatureAuthor Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2023 Mar; 615(7953):E23.Nature2023-03-01T00:00:002023Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.Authorship 10684919Authorship 10684605Authorship 1068376337015331Asare EA, Brookland RK, Gershenwald JE, Nelson H, Washington MKJournal of the National Comprehensive Cancer Network : JNCCNLetter to the Editor: Re: Reimagining Cancer Staging in the Era of Evolutionary Oncology. J Natl Compr Canc Netw. 2023 04; 21(4):xviii.J Natl Compr Canc Netw2023-04-01T00:00:002023Letter to the Editor: Re: Reimagining Cancer Staging in the Era of Evolutionary Oncology.37010038Asare EA, Fisher SB, Chiang YJ, Haydu LE, Patel SH, Keung EZ, Lucci A, Wargo J, Gershenwald JE, Ross MI, Lee JEJournal of surgical oncologyMelanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. J Surg Oncol. 2023 Aug; 128(2):313-321.J Surg Oncol2023-04-03T00:00:002023Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management.37072748Ascierto PA, Blank C, Eggermont AM, Garbe C, Gershenwald JE, Hamid O, Hauschild A, Luke JJ, Mehnert JM, Sosman JA, Tawbi HA, Mandal? M, Testori A, Carac? C, Osman I, Puzanov IJournal of translational medicineThe "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022. J Transl Med. 2023 04 18; 21(1):265.J Transl Med2023-04-18T00:00:002023The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.Authorship 107018230Authorship 1069570137149545Thompson JF, Hyngstrom J, Carac? C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Henderson M, Dummer R, Rossi CR, Kane JM, Trocha S, Wright F, Byrd DR, Matter M, MacKenzie-Ross A, Kelley MC, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, O'Donoghue C, Sardi A, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Testori AAE, Scolyer RA, Elashoff DE, Cochran AJ, Faries MBAnnals of surgical oncologyRegarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma. Ann Surg Oncol. 2023 07; 30(7):4359-4360.Ann Surg Oncol2023-05-06T00:00:002023Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.37162402Gershenwald JECancerMitotic rate in primary cutaneous melanoma: Cell division matters. Cancer. 2023 08 01; 129(15):2290-2293.Cancer2023-05-10T00:00:002023Mitotic rate in primary cutaneous melanoma: Cell division matters.Authorship 10757161Authorship 107555010Authorship 107581510Authorship 1075742437507765Ascierto PA, Agarwala SS, Warner AB, Ernstoff MS, Fox BA, Gajewski TF, Galon J, Garbe C, Gastman BR, Gershenwald JE, Kalinski P, Krogsgaard M, Leidner RS, Lo RS, Menzies AM, Michielin O, Poulikakos PI, Weber JS, Carac? C, Osman I, Puzanov I, Thurin MJournal of translational medicinePerspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 07 28; 21(1):508.J Transl Med2023-07-28T00:00:002023Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).37509290Lucci A, Addanki S, Chiang YJ, Meas S, Sarli VN, Upshaw JR, Manchem M, Patel SP, Wargo JA, Gershenwald JE, Ross MICancersPresence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma. Cancers (Basel). 2023 Jul 15; 15(14).Cancers (Basel)2023-07-15T00:00:002023Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma.37493893Gershenwald JEAnnals of surgical oncologyTop Melanoma Articles from 2021 to Inform Your Cancer Practice. Ann Surg Oncol. 2023 Oct; 30(11):6325-6331.Ann Surg Oncol2023-07-26T00:00:002023Top Melanoma Articles from 2021 to Inform Your Cancer Practice.37499671Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RALancet (London, England)Cutaneous melanoma. Lancet. 2023 08 05; 402(10400):485-502.Lancet2023-07-24T00:00:002023Cutaneous melanoma.Authorship 107733814Authorship 10774761137647056Witt RG, Cass SH, Tran T, Damania A, Nelson EE, Sirmans E, Burton EM, Chelvanambi M, Johnson S, Tawbi HA, Gershenwald JE, Davies MA, Spencer C, Mishra A, Wong MC, Ajami NJ, Peterson CB, Daniel CR, Wargo JA, McQuade JL, Nelson KCJAMA dermatologyGut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol. 2023 10 01; 159(10):1076-1084.JAMA Dermatol2023-10-01T00:00:002023Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma.37659660Cass S, Cope B, Bishop AJ, Chiang YJ, Ashleigh Guadagnolo B, Farooqi A, Morrison W, Witt RG, Seervai RNH, Garden AS, Fuller CD, Goepfert RP, Ross M, Gershenwald JE, Wong M, Aung PP, Keung EZ, Mitra DRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyPrimary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiother Oncol. 2023 Nov; 188:109892.Radiother Oncol2023-09-01T00:00:002023Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes.Authorship 10803061237804122Wei AZ, Chen LN, Orloff M, Ariyan CE, Asgari M, Barker CA, Buchbinder E, Chandra S, Couts K, Frumovitz MM, Futreal A, Gershenwald JE, Hanna EY, Izar B, LeBlanc AK, Leitao MM, Lipson EJ, Liu D, McCarter M, McQuade JL, Najjar Y, Rapisuwon S, Selig S, Shoushtari AN, Yeh I, Schwartz GK, Guo J, Patel SP, Carvajal RDPigment cell & melanoma researchProceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA). Pigment Cell Melanoma Res. 2023 Nov; 36(6):542-556.Pigment Cell Melanoma Res2023-10-07T00:00:002023Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA).Authorship 10883521738315961Varey AHR, Li I, El Sharouni MA, Simon J, Dedeilia A, Ch'ng S, Saw RPM, Spillane AJ, Shannon KF, Pennington TE, Rtshiladze M, Stretch JR, Nieweg OE, van Akkooi A, Sullivan RJ, Boland GM, Gershenwald JE, van Diest PJ, Scolyer RA, Long GV, Thompson JF, Lo SNJournal of clinical oncology : official journal of the American Society of Clinical OncologyPredicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator. J Clin Oncol. 2024 Feb 05; JCO2301020.J Clin Oncol2024-02-05T00:00:002024Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.Authorship 1088949838363565Maul LV, Jamiolkowski D, Lapides RA, Mueller AM, Hauschild A, Garbe C, Lorigan P, Gershenwald JE, Ascierto PA, Long GV, Wang-Evers M, Scolyer RA, Saravi B, Augustin M, Navarini AA, Legge S, N?meth IB, J?nosi ?J, Mocellin S, Feller A, Manstein D, Zink A, Maul JT, Buja A, Adhikari K, Roider EJAMA network openHealth Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe. JAMA Netw Open. 2024 Feb 05; 7(2):e2356479.JAMA Netw Open2024-02-05T00:00:002024Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professor